Low cardiac output syndrome (LCOS) is a clinical state in which the heart fails to deliver sufficient blood flow to meet the body's metabolic demands, typically defined as a cardiac index (CI) below 2.2 L/min/m² or cardiac output below 4 L/min with signs of tissue hypoperfusion. LCOS represents one of the most critical hemodynamic emergencies encountered in cardiology and critical care medicine. Prompt recognition, accurate hemodynamic assessment, and timely institution of pharmacological and mechanical support are essential to prevent irreversible end-organ damage.
Defining Low Cardiac Output
Low cardiac output is hemodynamically defined as a cardiac index below 2.2 L/min/m² or an absolute cardiac output below 4 L/min in the setting of clinical signs of tissue hypoperfusion. The clinical syndrome encompasses a spectrum ranging from mild hemodynamic compromise with preserved mentation and urine output to profound cardiogenic shock with multi-organ failure. The SCAI (Society for Cardiovascular Angiography and Interventions) shock classification provides a standardized staging system from stage A (at risk) through stage E (extremis) that helps guide escalation of therapy.
The hemodynamic profile of low cardiac output syndrome typically includes elevated filling pressures (pulmonary capillary wedge pressure > 18 mmHg), reduced cardiac index (< 2.2 L/min/m²), and increased systemic vascular resistance as the body attempts to maintain blood pressure through compensatory vasoconstriction. Mixed venous oxygen saturation (SvO₂) falls below 60% as tissues extract a greater fraction of delivered oxygen, and serum lactate rises as anaerobic metabolism ensues. These parameters collectively define the hemodynamic signature of cardiogenic shock.
The clinical significance of low cardiac output extends beyond the hemodynamic numbers. Persistent tissue hypoperfusion leads to progressive end-organ dysfunction including acute kidney injury (reduced renal perfusion), hepatic congestion and ischemia (cardiohepatic syndrome), impaired gastrointestinal motility and barrier function, and altered mental status. The mortality of cardiogenic shock remains approximately 40–50% despite advances in pharmacological and mechanical support, underscoring the importance of early recognition and aggressive management before irreversible organ damage occurs.
Causes of Low Cardiac Output
Left ventricular systolic dysfunction is the most common cause of low cardiac output, encompassing acute myocardial infarction (particularly anterior ST-elevation MI involving the left anterior descending artery territory), decompensated chronic heart failure with reduced ejection fraction (HFrEF), and acute myocarditis. In acute MI, cardiogenic shock occurs in approximately 5–8% of cases and carries the highest mortality. Mechanical complications of MI — including ventricular septal rupture, free wall rupture, and acute mitral regurgitation from papillary muscle rupture — can cause sudden catastrophic drops in cardiac output.
Right ventricular (RV) failure is an increasingly recognized cause of low cardiac output that is frequently underdiagnosed. Causes include right ventricular myocardial infarction, acute pulmonary embolism, acute respiratory distress syndrome (ARDS) with elevated pulmonary vascular resistance, and decompensated pulmonary hypertension. RV failure presents with a distinct hemodynamic profile: elevated right atrial pressure with low or normal pulmonary capillary wedge pressure, and reduced cardiac output due to inadequate left ventricular filling. Management differs fundamentally from left-sided failure, emphasizing volume optimization, RV-specific inotropes, and pulmonary vasodilators.
Additional causes of low cardiac output include severe valvular heart disease (acute aortic or mitral regurgitation, critical aortic stenosis), cardiac tamponade, constrictive pericarditis, and diastolic heart failure with severely impaired filling. Postcardiotomy low cardiac output syndrome occurs in 2–6% of patients after cardiac surgery, resulting from myocardial stunning, cardioplegia injury, or pre-existing ventricular dysfunction. Each etiology requires specific diagnostic evaluation and targeted treatment, making accurate identification of the underlying cause essential for effective management.
Diagnosis and Hemodynamic Assessment
Pulmonary artery (PA) catheterization remains the gold standard for comprehensive hemodynamic assessment in suspected low cardiac output syndrome. The PA catheter (Swan-Ganz catheter) provides direct measurement of right atrial pressure, pulmonary artery pressure, pulmonary capillary wedge pressure, and mixed venous oxygen saturation. Cardiac output is determined by either thermodilution or the Fick method, and derived parameters including cardiac index, systemic and pulmonary vascular resistance, stroke volume, and stroke work are calculated from these primary measurements.
Mixed venous oxygen saturation (SvO₂), measured from the distal port of the PA catheter in the pulmonary artery, is a critically important parameter in low cardiac output assessment. Normal SvO₂ ranges from 65–75%, and values below 60% indicate inadequate oxygen delivery relative to consumption — a hallmark of low cardiac output. Continuous SvO₂ monitoring via fiberoptic PA catheters provides real-time trending of the adequacy of global oxygen delivery and serves as an early warning system for hemodynamic deterioration before changes in blood pressure or other clinical signs become apparent.
Echocardiography provides essential complementary information including left and right ventricular size and function, valvular pathology, pericardial effusion, and estimation of cardiac output via Doppler methods. Point-of-care echocardiography is often the first diagnostic step in the acute setting, while formal transthoracic or transesophageal echocardiography provides definitive anatomic and functional assessment. Serum lactate measurement, trending of serum creatinine and liver function tests, and assessment of urine output complete the diagnostic evaluation of the patient with suspected low cardiac output syndrome.
Management Strategies
Pharmacological management of low cardiac output begins with inotropic agents that increase myocardial contractility. Dobutamine, a synthetic catecholamine with predominantly beta-1 adrenergic activity, is the first-line inotrope for cardiogenic shock, increasing cardiac output while modestly reducing afterload. Milrinone, a phosphodiesterase-3 inhibitor, provides combined inotropic and vasodilatory ("inodilator") effects and is particularly useful in patients with elevated pulmonary vascular resistance or chronic beta-blocker therapy. Vasopressors such as norepinephrine are added when systemic hypotension persists despite inotropic support, targeting a mean arterial pressure of at least 65 mmHg.
Mechanical circulatory support (MCS) devices are indicated when pharmacological therapy fails to restore adequate perfusion or when escalating doses of vasoactive agents produce diminishing returns. The intra-aortic balloon pump (IABP) provides modest augmentation of diastolic coronary perfusion and mild afterload reduction. The Impella device (percutaneous microaxial pump) provides greater hemodynamic support, directly unloading the left ventricle and augmenting cardiac output by 2.5–5.5 L/min depending on device size. Extracorporeal membrane oxygenation (ECMO), specifically veno-arterial ECMO, provides the highest level of circulatory support and serves as a bridge to recovery, durable LVAD implantation, or heart transplantation in refractory cardiogenic shock.
Frequently Asked Questions
What cardiac index value defines cardiogenic shock?
Cardiogenic shock is hemodynamically defined as a cardiac index below 2.2 L/min/m² in the presence of adequate or elevated filling pressures (PCWP > 18 mmHg) and clinical signs of tissue hypoperfusion. This corresponds to an absolute cardiac output typically below 4 L/min, though the indexed value is more clinically reliable.
What is mixed venous oxygen saturation and why does it matter in low cardiac output?
Mixed venous oxygen saturation (SvO₂) measures the oxygen saturation of blood in the pulmonary artery, reflecting the balance between oxygen delivery and consumption. Normal SvO₂ is 65–75%. In low cardiac output states, SvO₂ falls below 60% as tissues extract more oxygen, providing an early indicator of inadequate perfusion.
When is mechanical circulatory support used for low cardiac output?
Mechanical circulatory support (IABP, Impella, or ECMO) is indicated when pharmacological therapy with inotropes and vasopressors fails to restore adequate perfusion, when vasoactive medication doses become excessive, or when there is evidence of progressive end-organ dysfunction despite maximal medical therapy.